Knight Therapeutics Inc. (OTCMKTS:KHTRF) Short Interest Down 39.1% in November

Knight Therapeutics Inc. (OTCMKTS:KHTRF) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 341,000 shares, a decrease of 39.1% from the November 15th total of 560,000 shares. Based on an average daily trading volume, of 46,500 shares, the short-interest ratio is presently 7.3 days.

Knight Therapeutics Trading Down 0.5 %

Knight Therapeutics stock traded down $0.02 during mid-day trading on Thursday, hitting $3.73. 793 shares of the company’s stock traded hands, compared to its average volume of 5,802. Knight Therapeutics has a fifty-two week low of $3.65 and a fifty-two week high of $4.55. The firm has a 50 day simple moving average of $3.94 and a two-hundred day simple moving average of $4.11.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.